Alterity Therapeutics Ltd
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-… Read more
Alterity Therapeutics Ltd (ATHE) - Total Liabilities
Latest total liabilities as of December 2025: $2.65 Million USD
Based on the latest financial reports, Alterity Therapeutics Ltd (ATHE) has total liabilities worth $2.65 Million USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Alterity Therapeutics Ltd - Total Liabilities Trend (1998–2025)
This chart illustrates how Alterity Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Alterity Therapeutics Ltd Competitors by Total Liabilities
The table below lists competitors of Alterity Therapeutics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bhiraj Office Leasehold Real Estate Investment Trust
BK:BOFFICE
|
Thailand | ฿2.56 Billion |
|
ReproCELL Incorporated
F:6RC
|
Germany | €688.22 Million |
|
Kernel Holding SA
F:0KE
|
Germany | €1.23 Billion |
|
Anhui Xinbo Aluminum Co Ltd
SHE:003038
|
China | CN¥8.06 Billion |
|
Sappe Public Company Limited
BK:SAPPE
|
Thailand | ฿1.10 Billion |
|
Carlo Gavazzi Holding AG
SW:GAV
|
Switzerland | CHF39.69 Million |
|
Walchandnagar Industries Limited
NSE:WALCHANNAG
|
India | ₹5.17 Billion |
|
Compagnie d'Entreprises CFE S.A.
LSE:0O2T
|
UK | €3.16 Billion |
Liability Composition Analysis (1998–2025)
This chart breaks down Alterity Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 21.98 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Alterity Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Alterity Therapeutics Ltd (1998–2025)
The table below shows the annual total liabilities of Alterity Therapeutics Ltd from 1998 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $3.62 Million | -33.22% |
| 2024-06-30 | $5.43 Million | +20.44% |
| 2023-06-30 | $4.50 Million | -23.57% |
| 2022-06-30 | $5.89 Million | +89.20% |
| 2021-06-30 | $3.12 Million | +13.00% |
| 2020-06-30 | $2.76 Million | -17.83% |
| 2019-06-30 | $3.36 Million | +26.86% |
| 2018-06-30 | $2.64 Million | +66.25% |
| 2017-06-30 | $1.59 Million | -32.53% |
| 2016-06-30 | $2.36 Million | -13.35% |
| 2015-06-30 | $2.72 Million | -31.19% |
| 2014-06-30 | $3.95 Million | +27.60% |
| 2013-06-30 | $3.10 Million | +80.35% |
| 2012-06-30 | $1.72 Million | -17.37% |
| 2011-06-30 | $2.08 Million | +32.29% |
| 2010-06-30 | $1.57 Million | +85.51% |
| 2009-06-30 | $847.43K | -53.84% |
| 2008-06-30 | $1.84 Million | -12.97% |
| 2007-06-30 | $2.11 Million | +24.62% |
| 2006-06-30 | $1.69 Million | -36.93% |
| 2005-06-30 | $2.68 Million | -0.46% |
| 2004-06-30 | $2.70 Million | +377.62% |
| 2003-06-30 | $564.54K | -38.15% |
| 2002-06-30 | $912.82K | +2.04% |
| 2001-06-30 | $894.58K | +507.99% |
| 2000-06-30 | $147.14K | -92.33% |
| 1999-06-30 | $1.92 Million | +859.02% |
| 1998-06-30 | $199.96K | -- |